Tredje AP fonden Sells 5,389 Shares of The Clorox Company $CLX

Tredje AP fonden lessened its stake in The Clorox Company (NYSE:CLX) by 32.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,107 shares of the company’s stock after selling 5,389 shares during the period. Tredje AP fonden’s holdings in Clorox were worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of CLX. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Clorox by 9.0% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock valued at $40,285,000 after purchasing an additional 27,639 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Clorox during the 2nd quarter worth about $8,568,000. Vise Technologies Inc. acquired a new stake in shares of Clorox during the second quarter worth about $328,000. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Clorox by 64.2% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 25,732 shares of the company’s stock valued at $3,173,000 after acquiring an additional 10,065 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Clorox by 11.7% in the third quarter. ProShare Advisors LLC now owns 1,297,016 shares of the company’s stock valued at $159,922,000 after purchasing an additional 136,135 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Price Performance

Clorox stock opened at $123.51 on Monday. The company has a fifty day simple moving average of $109.75 and a 200-day simple moving average of $113.51. The company has a quick ratio of 0.48, a current ratio of 0.74 and a debt-to-equity ratio of 71.03. The firm has a market capitalization of $14.93 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 0.61 and a beta of 0.59. The Clorox Company has a 52-week low of $96.66 and a 52-week high of $159.04.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.04). The business had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 11.17% and a return on equity of 383.01%. The firm’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.55 EPS. On average, equities analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CLX. Barclays reiterated an “underweight” rating and issued a $109.00 target price on shares of Clorox in a research note on Friday, January 16th. UBS Group lifted their price target on Clorox from $115.00 to $121.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. JPMorgan Chase & Co. upped their price target on Clorox from $114.00 to $117.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Morgan Stanley boosted their price objective on Clorox from $125.00 to $136.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Finally, TD Cowen lifted their price target on shares of Clorox from $108.00 to $111.00 and gave the company a “hold” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Clorox has an average rating of “Reduce” and a consensus target price of $118.73.

Key Clorox News

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Zacks raised its FY2028 EPS view to $7.23 and upgraded select quarterly/annual estimates (including Q1 2028 to $1.37 and Q4 2026/2027 increases), signaling modestly better forward earnings visibility that can support the stock.
• Positive Sentiment: Clorox published a consumer research report “Home Care Redefined” that underscores evolving demand for wellness- and convenience-oriented home-care products — a strategic tailwind for branded consumer staples. Home Care Redefined
• Neutral Sentiment: Management presented at the Consumer Analyst Group of New York (CAGNY) conference; slides and prepared remarks provide more detail on strategy, cost actions and growth initiatives — useful for longer-term positioning but not an immediate earnings surprise. CAGNY Slides Transcript
• Negative Sentiment: Zacks trimmed multiple near-term quarterly EPS forecasts (several Q2–Q3 2026/2027 cuts and FY2027 lowered to $6.74), reflecting caution about near-term volume/mix or cost pressure — a potential headwind for sentiment and short-term guidance expectations.
• Negative Sentiment: Wells Fargo issued a “Hold” on CLX (reported as “receives a Hold”), which keeps sell-side sentiment neutral-to-cautious and may limit near-term upside from upgrades. Wells Fargo Hold

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.